Humacyte (NASDAQ: HUMA) warned on Nasdaq $1 bid rule, given 180 days
Rhea-AI Filing Summary
Humacyte, Inc. received a Nasdaq notice that its common stock bid price closed below the $1.00 per share minimum for 30 consecutive business days ended July 30, 2026, violating Nasdaq Listing Rule 5450(a)(1).
Under Nasdaq Listing Rule 5810(c)(3)(A), Humacyte has 180 calendar days, until January 27, 2027, to regain compliance by achieving a closing bid of at least $1.00 per share for a minimum of 10 consecutive business days. The notice has no immediate effect on the Nasdaq Global Select Market listing, trading symbol HUMA, or on business operations, while the company monitors its stock price and evaluates options.
Positive
- None.
Negative
- Nasdaq $1.00 bid deficiency: Humacyte’s common stock closed below the $1.00 minimum bid for 30 consecutive business days, triggering a Nasdaq notice and a 180-day cure period, creating a risk of delisting if compliance is not regained.
Filing Explained
The Nasdaq deficiency remains unresolved: written confirmation and closure would follow only after compliance is regained, and the filing gives no assurance that this will occur.
8-K Event Classification
Item 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
1 item
Item 3.01
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Securities
The company received a delisting notice or transferred its listing to a different exchange.
Key Figures
Consecutive days below minimum bid: 30 consecutive business days
Minimum bid requirement: $1.00 per share
Initial cure period: 180 calendar days
+2 more
5 metrics
Consecutive days below minimum bid
30 consecutive business days
Period ended July 30, 2026 when bid price was below $1.00 per share
Minimum bid requirement
$1.00 per share
Nasdaq Listing Rule 5450(a)(1) continued listing standard
Initial cure period
180 calendar days
Time provided under Nasdaq Listing Rule 5810(c)(3)(A) to regain compliance
Compliance deadline
January 27, 2027
End of initial 180-day period to restore Nasdaq bid-price compliance
Required compliant trading days
10 consecutive business days
Minimum span the closing bid must be at or above $1.00 per share
Key Terms
Nasdaq Listing Rule 5450(a)(1), Nasdaq Listing Rule 5810(c)(3)(A), continued listing, bid price
4 terms
Nasdaq Listing Rule 5450(a)(1) regulatory
"minimum $1.00 per share requirement for continued listing under Nasdaq Listing Rule 5450(a)(1)"
Nasdaq Listing Rule 5450(a)(1) is a continued-listing standard that sets a minimum share price companies must maintain to remain listed on the Nasdaq market—commonly a $1.00 per-share threshold. Investors care because falling below that floor can trigger a compliance review and possible delisting, which is like failing a minimum grade and losing access to the public market; delisting can reduce liquidity, visibility and the ability to raise capital.
Nasdaq Listing Rule 5810(c)(3)(A) regulatory
"In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has 180 days to regain compliance"
continued listing regulatory
"continued listing on The Nasdaq Global Select Market under Nasdaq Listing Rule 5450(a)(1)"
When a stock receives a "continued listing," it means the exchange has decided the company’s shares will remain tradable on that market after a review or challenge, often because the company met certain requirements or corrective steps. For investors this matters because continued listing preserves liquidity and access to buy or sell the stock—think of it as a store passing an inspection so customers can keep shopping rather than being forced to close.
bid price market
"the bid price for the Company’s common stock had closed below the minimum $1.00 per share requirement"
The bid price is the highest price a buyer is willing to pay for a share or other security at a given moment. Think of it as the offer a shopper makes at an auction — it shows what you could sell for right now if you accepted the highest buyer. Investors watch the bid because it affects how quickly a sale will execute and how much they’ll actually receive after accounting for the gap between buyer and seller prices.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What Nasdaq compliance issue did Humacyte (HUMA) disclose?
Humacyte disclosed that Nasdaq notified it the stock’s bid price was below the $1.00 per share minimum for 30 consecutive business days, breaching Nasdaq Listing Rule 5450(a)(1). This began a formal compliance period to cure the deficiency and avoid potential delisting.
How long does Humacyte (HUMA) have to regain Nasdaq compliance?
Humacyte has an initial 180 calendar days, until January 27, 2027, to regain compliance under Nasdaq Listing Rule 5810(c)(3)(A). Within this window, the company must meet the bid price requirement or potentially face additional Nasdaq actions regarding its listing status.
Does the Nasdaq notice immediately affect Humacyte (HUMA) stock trading or operations?
The notice has no immediate effect on Humacyte’s listing or operations. Its common stock continues to trade on the Nasdaq Global Select Market under the symbol HUMA, and the company’s business operations and SEC reporting obligations remain unchanged during the compliance period.